Extended Data Fig. 9: Nanostring validation by flow cytometry.
K14-Cre Brca1f/fTrp53f/f tumor bearing mice were treated for 5 days (n = 6 mice/group). a, Tumor volume after 5 days of treatment. b, Therapy was well tolerated. Statistical analysis was performed using a 2-way ANOVA with Turkey test *P < 0.05. c-j, Tumors were collected and immunophenotyped by flow cytometry. c, Olaparib and the combination of anti-CSF-1R plus Olaparib significantly increased total leukocyte infiltration (CD45+). Anti-CSF-1R significantly decreased the macrophage population as indicated by F480+ cells. d, The proportion of neutrophils (Gr1+) and myeloid derived suppressor cells (CD11b+Gr1+) are shown. e, Anti-CSF-1R plus Olaparib increased the number of macrophages (CD45+F480+) that expressed the pro-inflammatory cytokines IL-1α and its receptors (IL-1R1+, IL-1R2+) whereas Olaparib treatment increased macrophages expressing IL-1β. f, Olaparib, anti-CSF-1R and the combination of anti-CSF-1R plus Olaparib increased the frequency of macrophages (CD45+F480+) expressing TNFα, yet induced variable expression of its receptors CD120a and CD120b. The frequency of myeloid cells CD11b+ (g) and dendritic cells (i) expressing the pro-inflammatory cytokines IL-1β and IL-1α and their receptors (IL-1R1 and IL-1R2) increased after Olaparib treatment and further increased with anti-CSF-1R plus Olaparib treatment. h,j, Similar changes were seen for TNFα and its receptors CD120a and CD120b. Error bars represent standard error of mean (±SEM). Statistical analyses were performed using two-way ANOVA with uncorrected Fisher’s LSD. Exact p values indicated in each panel for each comparison.
